|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
|
Companies’ continued reliance on manual processes and disparate labelling systems often culminates in pricey product recalls. In 2018, the return of over a million units and 9% of all medical device recall events were due to labelling issues. Organisations are known to spend as much as US $350,000 for every global label change. However, despite opportunities to de-risk the process through automated technologies, many persist with archaic methodologies that leave them vulnerable to human error. This absurdity is as unsustainable as it is avoidable.
As global regulations stiffen and the cost of noncompliance climbs, manufacturers must find a method to end the madness. Those who do will not only remove risk from their business, they will unlock the potential for additional cost savings that could transform the bottom line.
Labelling errors are a recurring reality for medical devices. The scale of the problem has barely shifted since 2012 when, just like now, around 10% of product recalls were label related. However, as label content becomes more complex with the introduction of new regulations, this figure will only increase if companies do not proactively review and strengthen their labelling infrastructure. The telltale signs of suboptimal operations are evident in the most prevalent causes of labelling recalls.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator, with the UK and France close behind
Paris, 19th August 2019: As predicted by the ‘European drug delivery and packaging’ report earlier this year, new data shows innovation in drug delivery is accelerating across Europe – with provisional findings from the Pharmapack Innovation Index (2020) showing that Switzerland has over taken Germany as Europe’s most innovative drug delivery market.
More info >> |
|
 |
White Papers |
 |
|
Choosing the Right CMO for HPAPI Manufacturing
AMRI
Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >> |
|
 |
Industry Events |
 |
FlyPharma Europe
22-23 October 2019, Copenhagen, Denmark
The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and
businesses that are ready to uncover the potential in their pharma supply chain. The
event offers an interactive platform to discuss current and future challenges within
pharma and cargo, with topics including market trends, cold chain innovations, latest
regulatory demands, security technology, and how to encourage collaboration between
supply chain players.
There will be plenty of networking opportunities, including a complimentary evening
networking event, where delegates can meet and catch up with senior and executive
pharma
and cargo professionals – gaining strong, new industry contacts and building on
existing ones.
More info >> |
|
|
